Belvedere Trading
VIR icon

Belvedere Trading’s Vir Biotechnology VIR Stock Holding History

Belvedere Trading’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,511
Closed -$135K – 968
2023
Q2 		$135K Buy
5,511
+3,164
+135% +$79.5K ﹤0.01% 381
2023
Q1 		$54.6K Buy
+2,347
New +$60K ﹤0.01% 570

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Belvedere Trading's VIR Position: Q3 2023 in Review

Belvedere Trading sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 5,511 shares — an estimated $135K sold.

Belvedere Trading first reported a position in VIR in Q1 2023 and held it in 2 quarters. The position peaked at $135K in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Belvedere Trading reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 5,511 Vir Biotechnology shares in Q3 2023, an estimated $135K.
  • Belvedere Trading first reported a position in Vir Biotechnology in Q1 2023 and held it in 2 quarters.
  • Belvedere Trading's Vir Biotechnology position peaked at $135K in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.